iiinova — where your digital self keeps evolving

Meral KAYIKCIOGLU

@meralkayikcioglu.bsky.social

Meral KAYIKCIOGLU @meralkayikcioglu.bsky.social · 23/04/2025

Honored to speak at UKRAINE & EUROPE: UNITING HEARTS, organized by Ukrainian Atherosclerosis Society. I was deeply moved to join as an online speaker to support Ukrainian Colleagues during the most difficult circumstances. @eassociety.bsky.social @erinmichos.bsky.social

242

Reposted by Meral KAYIKCIOGLU

Meral KAYIKCIOGLU @meralkayikcioglu.bsky.social · 14/04/2025

Honored to speak at #Riga Lipid Conference 2025— My topic was “Homozygous FH: Clinical Approach & International Registries,” A heartfelt thank to Prof. Gustavs Latkovskis for his impeccable organization & kind hospitality. It was a pleasure to join esteemed colleagues @eassociety.bsky.social

052

Meral KAYIKCIOGLU @meralkayikcioglu.bsky.social · 14/04/2025

052

Reposted by Meral KAYIKCIOGLU

Erin Michos, MD @erinmichos.bsky.social · 29/03/2025

Exciting! #STRIDE trial just presented at #ACC25 @accintouch.bsky.social . #Semaglutide improved mean walking distance, symptoms, major limb events & quality of life in patients with #T2D & #PAD. We have a new drug now to help PAD patients! #CardioSky

11510

Reposted by Meral KAYIKCIOGLU

Erin Michos, MD @erinmichos.bsky.social · 29/03/2025

#SOUL trial presented at #ACC25. Oral #semaglutide reduced 3-pt major adverse cardiovascular events by 14% in patients with T2D, even with high background SGLTi use. In exploratory analysis, oral sema also reduced major limb events. #CardioSky @accintouch.bsky.social

12114

Reposted by Meral KAYIKCIOGLU

Erin Michos, MD @erinmichos.bsky.social · 31/03/2025

Exciting new development in lipid field! The early Phase 2 #PURSUIT trial showed a novel oral #PCSK9i (that can be taken with food) lowered LDL-C by 51% at 12 weeks. 84% achieved LDL-C of <70 mg/dL. #ACC25 @accintouch.bsky.social

01510